Bright Minds Biosciences Inc. (DRUG)

Bright Minds Biosciences Statistics

Total Valuation

DRUG has a market cap or net worth of $749.19 million. The enterprise value is $526.17 million.

Market Cap	749.19M
Enterprise Value	526.17M

Important Dates

The next estimated earnings date is Tuesday, June 16, 2026, after market close.

Earnings Date	Jun 16, 2026
Ex-Dividend Date	n/a

Share Statistics

DRUG has 9.81 million shares outstanding. The number of shares has increased by 42.99% in one year.

Current Share Class	9.81M
Shares Outstanding	9.81M
Shares Change (YoY)	+42.99%
Shares Change (QoQ)	+23.56%
Owned by Insiders (%)	16.34%
Owned by Institutions (%)	61.92%
Float	5.17M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	3.39
P/TBV Ratio	3.39
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 81.48, with a Debt / Equity ratio of 0.00.

Current Ratio	81.48
Quick Ratio	81.10
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-642.68

Financial Efficiency

Return on equity (ROE) is -15.02% and return on invested capital (ROIC) is -10.56%.

Return on Equity (ROE)	-15.02%
Return on Assets (ROA)	-10.44%
Return on Invested Capital (ROIC)	-10.56%
Return on Capital Employed (ROCE)	-9.98%
Weighted Average Cost of Capital (WACC)	3.20%
Revenue Per Employee	n/a
Profits Per Employee	-$753,699
Employee Count	26
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +162.78% in the last 52 weeks. The beta is -0.19, so DRUG's price volatility has been lower than the market average.

Beta (5Y)	-0.19
52-Week Price Change	+162.78%
50-Day Moving Average	82.72
200-Day Moving Average	71.66
Relative Strength Index (RSI)	37.02
Average Volume (20 Days)	280,516

Short Selling Information

The latest short interest is 756,484, so 7.71% of the outstanding shares have been sold short.

Short Interest	756,484
Short Previous Month	751,049
Short % of Shares Out	7.71%
Short % of Float	14.62%
Short Ratio (days to cover)	4.05

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-22.07M
Pretax Income	-19.60M
Net Income	-19.60M
EBITDA	n/a
EBIT	-22.07M
Earnings Per Share (EPS)	-$2.48

Balance Sheet

The company has $221.86 million in cash and $58,838 in debt, with a net cash position of $221.81 million or $22.61 per share.

Cash & Cash Equivalents	221.86M
Total Debt	58,838
Net Cash	221.81M
Net Cash Per Share	$22.61
Equity (Book Value)	221.03M
Book Value Per Share	22.53
Working Capital	220.98M

Cash Flow

Operating Cash Flow	-14.21M
Capital Expenditures	n/a
Depreciation & Amortization	52,150
Net Borrowing	-74,883
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

DRUG does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-42.99%
Shareholder Yield	-42.99%
Earnings Yield	-2.62%
FCF Yield	n/a

Analyst Forecast

The average price target for DRUG is $168.87, which is 126.92% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$168.87
Price Target Difference	126.92%
Analyst Consensus	Strong Buy
Analyst Count	7
Revenue Growth Forecast (3Y)	n/a
EPS Growth Forecast (3Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on July 14, 2023. It was a reverse split with a ratio of 1:5.

Last Split Date	Jul 14, 2023
Split Type	Reverse
Split Ratio	1:5

Scores

Altman Z-Score	n/a
Piotroski F-Score	1